Deciphera Pharmaceuticals, Inc. (DCPH)

NASDAQ: DCPH · IEX Real-Time Price · USD
8.04
-0.11 (-1.35%)
At close: Jan 21, 2022 4:00 PM
8.05
0.01 (0.12%)
After-hours:Jan 21, 2022 7:35 PM EST
Market Cap470.19M
Revenue (ttm)91.44M
Net Income (ttm)-274.31M
Shares Out58.48M
EPS (ttm)-4.75
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,301,664
Open8.12
Previous Close8.15
Day's Range8.02 - 8.37
52-Week Range7.63 - 52.43
Beta1.51
AnalystsBuy
Price Target12.22 (+52.0%)
Earnings DateFeb 7, 2022

About DCPH

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment...

IndustryBiotechnology
IPO DateSep 28, 2017
CEOSteven Hoerter
Employees350
Stock ExchangeNASDAQ
Ticker SymbolDCPH
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for DCPH stock is "Buy." The 12-month stock price forecast is 12.22, which is an increase of 51.99% from the latest price.

Price Target
$12.22
(51.99% upside)
Analyst Consensus: Buy

News

Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2022 Corporate Milestones

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

1 week ago - Business Wire

Deciphera Pharmaceuticals, Inc. to Present at the 40th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. ...

2 weeks ago - Business Wire

Deciphera Announces Approval of QINLOCK® in the United Kingdom for the Treatment of Fourth-Line Gastrointestinal Stro...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

1 month ago - Business Wire

Deciphera: Why There Won't Be a Quick Recovery

Traders might look at DCPH stock for a quick bounce after its 75% decline. But here's why that's not a great idea.

1 month ago - InvestorPlace

Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report?

Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs

Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.

1 month ago - Zacks Investment Research

Why Deciphera Pharmaceuticals Shot 12% Higher Today

The company announced a comprehensive restructuring program.

1 month ago - The Motley Fool

Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard

Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.

1 month ago - InvestorPlace

Deciphera Pharma Stock Rises After Announcing Corporate Restructuring

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors. Deciphera will implement an organizati...

1 month ago - Benzinga

Don't Bet on a Deciphera Stock Comeback

Qinlock's potential is severely limited, and the rest of Deciphera's pipeline is far from the commercialization stage. With this, expect DCPH stock to remain a clear-cut "avoid" situation.

1 month ago - InvestorPlace

Deciphera Pharmaceuticals Announces Restructuring to Prioritize Clinical Development Programs and Streamline Commerci...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

1 month ago - Business Wire

Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why

Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.

1 month ago - Zacks Investment Research

Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST

The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.

2 months ago - Zacks Investment Research

Deciphera's Qinlock Approved In Europe For Gastric Cancer

The European Commission has approved Deciphera Pharmaceuticals Inc's (NASDAQ: DCPH) Qinlock (ripretinib)for adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior tre...

2 months ago - Benzinga

Deciphera Receives European Commission Approval of QINLOCK® for the Treatment of Fourth-Line Gastrointestinal Stromal...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

2 months ago - Business Wire

Take a Bearish Stance on Bruised and Battered Deciphera Pharmaceuticals

Unfavorable clinical results and a wide earnings miss will undoubtedly sink DCPH stock. Resist the temptation to buy the dip.

2 months ago - InvestorPlace

DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging 70%?

Today, investors in Deciphera Pharmaceuticals and DCPH stock have seen tremendous selling pressure take this stock to all-time lows. The post DCPH Stock Alert: Why Is Deciphera Pharmaceuticals Plunging ...

2 months ago - InvestorPlace

Deciphera Pharmaceuticals opened 75% down on Friday: explore why

Shares of Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) tanked 75% on Friday morning after the U.S. firm said its INTRIGUE Phase III Clinical Study failed to meet the primary endpoint. The sharp decline ...

2 months ago - Invezz

Why Did Deciphera Stock Plunged 70% Today?

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor ...

2 months ago - Benzinga

Why Did Deciphera Stock Plunge 70% Today?

Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) stock plunged to a 52-week after announcing disappointing results from the INTRIGUE Phase 3 study of Qinlock in patients with gastrointestinal stromal tumor ...

2 months ago - Benzinga

Deciphera Pharmaceuticals Announces Top-Line Results from the INTRIGUE Phase 3 Clinical Study

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, ...

2 months ago - Business Wire

Deciphera (DCPH) Q3 Loss Wider Than Expected, Revenues Miss

Deciphera (DCPH) reports wider-than-expected loss and revenue miss in the third quarter. It is gearing up for multiple developments and pipeline updates in the fourth quarter.

2 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Misses Revenue Estimates

Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -6.20% and -2.14%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for...

2 months ago - Zacks Investment Research

Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2021 Financial Results

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update. “In the t...

2 months ago - Business Wire

Deciphera Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call and Webcast on No...

WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its third quarter 2021 financial results on Tuesday, November 2, 2021. In connection w...

2 months ago - Business Wire